Neuroendocrine and Metabolic Disorder Solutions
Changing the Face of Oral Absorption Drugs
OUR PIONEERING LIP'RAL TECHNOLOGY ENABLES EFFICIENT ABSORPTION OF WATER INSOLUBLE DRUGS.
Our unique technology, coupled with our product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b)(2) regulatory pathway strategy. We are focused on metabolic and endocrine disorders such as:
- Liver Disease (NASH)
- Low Testosterone (Hypogonadism)
- Recurrent Pre-Term Birth
- Postpartum Depression
Press Releases
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024 SALT LAKE CITY, May 1, 2024 /PRNewswire/ -- Lipocine Inc....